SG60073A1 - Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors - Google Patents

Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors

Info

Publication number
SG60073A1
SG60073A1 SG1997002068A SG1997002068A SG60073A1 SG 60073 A1 SG60073 A1 SG 60073A1 SG 1997002068 A SG1997002068 A SG 1997002068A SG 1997002068 A SG1997002068 A SG 1997002068A SG 60073 A1 SG60073 A1 SG 60073A1
Authority
SG
Singapore
Prior art keywords
mirtazapine
pharmaceutical composition
serotonin reuptake
reuptake inhibitors
selective serotonin
Prior art date
Application number
SG1997002068A
Other languages
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG60073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of SG60073A1 publication Critical patent/SG60073A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG1997002068A 1996-06-19 1997-06-16 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors SG60073A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
SG60073A1 true SG60073A1 (en) 1999-02-22

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1997002068A SG60073A1 (en) 1996-06-19 1997-06-16 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors

Country Status (25)

Country Link
US (1) US5977099A (ko)
JP (2) JP4925074B2 (ko)
KR (1) KR100481254B1 (ko)
CN (1) CN1132581C (ko)
AR (1) AR007609A1 (ko)
AT (1) ATE213159T1 (ko)
AU (1) AU727851B2 (ko)
BR (1) BR9703624A (ko)
CA (1) CA2208199C (ko)
CZ (1) CZ290691B6 (ko)
DE (1) DE69710390T2 (ko)
DK (1) DK0813873T3 (ko)
ES (1) ES2172744T3 (ko)
HK (1) HK1006081A1 (ko)
HU (1) HU225534B1 (ko)
ID (1) ID17051A (ko)
IL (1) IL121076A (ko)
NO (1) NO313177B1 (ko)
NZ (1) NZ328113A (ko)
PL (1) PL188520B1 (ko)
PT (1) PT813873E (ko)
RU (1) RU2181287C2 (ko)
SG (1) SG60073A1 (ko)
TR (1) TR199700522A3 (ko)
ZA (1) ZA975335B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL135825A0 (en) * 1997-11-14 2001-05-20 Akzo Nobel Nv Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
IL150289A0 (en) * 2000-01-19 2002-12-01 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ATE380884T1 (de) * 2001-02-12 2007-12-15 Organon Nv Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
ES2295677T3 (es) 2002-12-27 2008-04-16 Otsuka Pharmaceutical Co., Ltd. Derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del estado de animo.
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
ES2344440T3 (es) 2006-11-09 2010-08-26 Orexigen Therapeutics, Inc. Formulaciones farmaceuticas en capas que comprenden una capa intermedia de disolucion rapida.
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP5198660B2 (ja) 2009-06-09 2013-05-15 住友重機械工業株式会社 ハイブリッド式ショベル及びその制御方法
WO2011059207A2 (en) * 2009-11-13 2011-05-19 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
ATE99943T1 (de) * 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
CN1155410C (zh) * 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物

Also Published As

Publication number Publication date
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
DK0813873T3 (da) 2002-05-27
CA2208199C (en) 2006-10-24
HK1006081A1 (en) 1999-02-12
ES2172744T3 (es) 2002-10-01
NO972816D0 (no) 1997-06-18
IL121076A (en) 2000-10-31
CN1132581C (zh) 2003-12-31
BR9703624A (pt) 1998-09-01
AU2612997A (en) 1998-01-08
KR980000447A (ko) 1998-03-30
TR199700522A2 (xx) 1998-01-21
AU727851B2 (en) 2001-01-04
CN1173330A (zh) 1998-02-18
HUP9701068A3 (en) 2000-07-28
DE69710390D1 (de) 2002-03-21
NZ328113A (en) 1999-09-29
HUP9701068A2 (hu) 1998-08-28
AR007609A1 (es) 1999-11-10
CA2208199A1 (en) 1997-12-19
CZ290691B6 (cs) 2002-09-11
ID17051A (id) 1997-12-04
JP2009137970A (ja) 2009-06-25
MX9704579A (es) 1998-07-31
RU2181287C2 (ru) 2002-04-20
PT813873E (pt) 2002-06-28
US5977099A (en) 1999-11-02
JP4925074B2 (ja) 2012-04-25
ZA975335B (en) 1998-01-26
TR199700522A3 (tr) 1998-01-21
NO972816L (no) 1997-12-22
HU9701068D0 (en) 1997-08-28
JPH1067663A (ja) 1998-03-10
PL320628A1 (en) 1997-12-22
DE69710390T2 (de) 2002-08-14
ATE213159T1 (de) 2002-02-15
KR100481254B1 (ko) 2005-09-12
CZ187097A3 (cs) 1998-01-14
PL188520B1 (pl) 2005-02-28
NO313177B1 (no) 2002-08-26

Similar Documents

Publication Publication Date Title
HK1006081A1 (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL147246A0 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
IL122447A0 (en) Pharmaceutical composition with anaestheric effect
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
HUP0004561A3 (en) Dihydrobenzofurans, pharmaceutical compositions containing them and use thereof
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP9902668A3 (en) Piperazine derivatives, pharmaceutical compositions containing them and their use
HU9700955D0 (en) Substituted 2-naphtoylguanidine derivatives, their production, their use and pharmaceutical compositions containing them
IL140742A0 (en) Raloxifene and pharmaceutical composition comprising the same
NZ331461A (en) Benzothiophenes, formulations containing same, and methods
HUP0000203A3 (en) Naphthyl derivatives, pharmaceutical compositions containing them and intermediates
AU1193199A (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists
HUP9802590A3 (en) Indan-, benzothiophene-, benzofuran- and indolesulfonamide derivatives, their use and pharmaceutical compositions containing them
HU9700954D0 (en) Substituted 1-naphtoylguanidine derivatives, their production, their use and pharmaceutical compositions containing them
GB9623962D0 (en) Pharmaceutical composition
HUP0103006A3 (en) Substituted betha-diketones, pharmaceutical compositions containing them and their use
HU9602190D0 (en) Pharmaceutical composition against poultry coccidiosis
HUP9904402A3 (en) Polyhydroxyphenol derivatives, their use and pharmaceutical compositions containing them
IL121798A0 (en) 1-carba-(dethia)-cephalosporin derivatives their manufacture and pharmaceutical compositions containing them
ZA200110325B (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same.
HUP9903500A3 (en) Thiophene-, furane- and pyrrolesulfonamides, their use and pharmaceutical compositions containing them
GB9604426D0 (en) Pharmaceutical composition and use thereof
GB9611530D0 (en) Pharmaceutical composition